A randomised trial comparing the safety and efficacy of the Zoladex 10.8 mg depot, administered every 12 weeks, to that of the Zoladex 23,6 mg depot, administered every 4 weeks, in patients with advanced prostate cancer
SourceMedisch Contact, 27, 1, (1995), pp. 43-46
Article / Letter to editor
Display more detailsDisplay less details
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.